Antiretroviral and Antiparasitic Therapy Management in an Expatriate Patient with Loiasis and HIV: A Case ReportRiccardi N*, Magnè F, Saffioti C, Dodi F, Ferrazin A, Ratto S,Di Biagio A,Viscoli C
Division of Infectious Disease, IRCCS AOUS San Martino-IST-University of Genoa-Italy
- *Corresponding Author:
- Niccolò Riccardi
Infectious Disease Clinic
IRCCS AOU San Martino Hospital IST
University of Milan, IRRCS AOU
San Martino University Hospital-IST
L.go R. Benzi, 10, 16132 Genoa, Italy
Tel: +39 010 5554652
E-mail: [email protected]
Received Date: August 31, 2015; Accepted Date: September 01, 2015; Published Date: September 17, 2015
Citation: Riccardi N, Magnè F, Saffioti C, Dodi F, Ferrazin A, et al., (2015) Antiretroviral and Antiparasitic Therapy Management in an Expatriate Patient with Loiasis and HIV: A Case Report. J Trop Dis 4:178. doi:10.4172/2329-891X.1000178
Copyright: © 2015 Riccardi N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loa loa filariasis, endemic in Western and Central Africa, is rarely observed in Italy (about 100 cases reported between 1993 and 2013). Clinical manifestations of loiasis are different between expatriates and natives: asymptomatic infestation and eye involvement are more common in natives, while Calabar swelling, itching and urticaria are mainly seen in expatriates. Although a geographically restricted infection, it is not impossible to face loiasis among immigrants and travellers. Due to the HIV high prevalence in the same areas, also in apparent absence of risk factors or HIV related symptoms, an HIV test should be offered to people coming from these countries to detect unknown infections. We describe a case of symptomatic loiasis in an expatriate man, who was hospitalized for loiasis and discovered to be also HIV-1-positive; in our patient, the diagnosis of HIV infection forced us to start highly-active-antiretroviral therapy (HAART) and antiparasitic treatment simultaneously.